Pfizer/BioNTech Complete European Submission For Omicron Subvariant Adapted Vaccine
[ad_1] Longeveron Inc. LGVN announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No. 15861319.0) related to…
US Government To Purchase Additional Influenza Treatment From BioCryst For Pandemic Preparedness
[ad_1] Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. SPRC, a specialty clinical-stage…
Erytech Pharma Culls Work On Late-Stage Leukemia Asset, Evaluates Partnership Options
[ad_1] Pressure BioSciences Inc. PBIO, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty-testing services to the worldwide cosmetics, nutraceuticals, biotherapeutics and food/beverage industries,…
Owl Creek Urges Cano Health Board To Consider Potential Sale
[ad_1] Owl Creek Asset Management L.P. sent a letter to Cano Health Inc CANO board strongly encouraging the company to pursue strategic alternatives, including a potential sale. Owl Creek owns around a 3.75% stake…
Pfizer/BioNTech’s COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers
[ad_1] In 2017, 41.9% of Americans experienced some level of obesity. Adults experiencing obesity in 2019 spent an average of $1,861 more on medical expenses than people with a healthy…
Novo Nordisk’s Subcutaneous Semaglutide Shows Positive Action In Type 2 Diabetes
[ad_1] Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being…
FDA Approves Novavax’s COVID-19 Vaccine For Use In Adolescents
[ad_1] Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being…
Cue Health’s Molecular COVID-19 Test At Par With Lab Based PCR Tests
[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
Amid Dwindling Quarterly Sales, Sema4 Announces More Layoffs
[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
Saudi Public Investment Fund Picks Shares In Alphabet, Zoom, Microsoft
[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
Baby Formula Startup Seeks To Compete Abbott With 15% Market Share: Report
[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
Lexaria Bioscience’ Tech Processed Cannabidiol Receives Positive FDA Feedback For Hypertension
[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc MRSN announced a global…
Thumbs Down For Acadia’s Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia’s Encouraging Data In Brain Metastases: Biotech Daily
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: FDA Signs Off Marker Therapeutics Cell Therapy Study In Lymphoma Setting The FDA cleared Marker Therapeutics…
Becton Dickinson Forecasts Higher Sales From COVID-19 Diagnostic Testing Revenues
[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
Biotech Daily: Merck’s Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac’s COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: Alnylam Reports Upbeat Data From Amyloidosis Study Alnylam Pharmaceuticals Inc’s ALNY APOLLO-B Phase 3 study of…
Gilead Sciences’ Q2 Beats Street View On Robust Oncology, HIV Product Sales
[ad_1] Gilead Sciences Inc GILD reported Q2 sales of $6.26 billion, +1% Y/Y, beating the consensus of $5.86 billion, driven by increased sales of HIV and oncology products, partially offset by…
Conmed’s New Acquisition Is ‘Door-Opener’ For Orthopedic Surgery Business, This Analyst Says
[ad_1] Earlier today, CONMED Corporation CNMD agreed to acquire privately held Biorez Inc for $85 million and up to $165 million in commercial-based milestones. Biorez commercializes its BioBrace implant, a bioinductive scaffold used to…
Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
[ad_1] Axonics Inc AXNX reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million. Sacral neuromodulation (SNM) revenue was $55.8 million, and Bulkamid…
SEC Charges 11 People In $300M Crypto Ponzi Scheme
[ad_1] The Securities and Exchange Commission has charged 11 people for their roles in creating and promoting an allegedly fraudulent crypto-focused pyramid & Ponzi scheme that raised more than $300 million…
Immutep’s Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment
[ad_1] Immutep Limited IMMP announced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase 2 TACTI-002 trial. Part B evaluates Immutep’s lead product…
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
[ad_1] Innate Pharma SA’s IPHA futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc AZN did not meet a pre-defined threshold for efficacy. Based on this result and…
Amgen (AMGN) To Fight Internal Revenue Service (IRS) After $10.7 Billion Tax Bill
[ad_1] Amgen Inc AMGN will fight Internal Revenue Service over the company’s international tax strategy and $10.7 billion in back taxes and penalties, Wall Street Journal reported. The IRS agency…
Why Kazia Therapeutics (KZIA) Shares Are Plunging Today
[ad_1] Kazia Therapeutics Limited KZIA said GBM AGILE, a pivotal study for paxalisib in newly diagnosed glioblastoma, did not meet pre-defined criteria for continuing to a second stage. Patients enrolled in…
Why Celyad Oncology (CYAD) Shares Are Surging Today
[ad_1] The FDA has lifted the clinical hold on Celyad Oncology SA’s CYAD CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the company made changes to the eligibility criteria for the trial. “We remain…